Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    "Gaucher disease type 1"
Show Display Options
RSS Create an RSS feed from your search for:
"Gaucher disease type 1"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease Type 1
Intervention: Drug: N-acetylcysteine
2 Completed
Has Results
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
Conditions: Gaucher Disease, Type 1;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme
3 Completed
Has Results
Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Condition: Type 1 Gaucher Disease
Intervention: Drug: miglustat
4 Recruiting The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Conditions: Gaucher Disease Type 1;   Gaucher Disease Type 3
Intervention: Drug: Velaglucerase alfa
5 Completed Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease
Condition: Gaucher Disease Type 1
Intervention: Device: BeamMed Speed-of-Sound bone strength test at forearm
6 Completed A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients
Conditions: Gaucher Disease;   Type 1 Gaucher Disease;   Gaucher Disease, Type 1
Intervention: Drug: AT2101
7 Terminated A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101
Condition: Type 1 Gaucher Disease
Intervention: Drug: AT2101
8 Completed
Has Results
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
Conditions: Gaucher Disease, Type 1;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Eliglustat tartrate
9 Completed A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
Conditions: Gaucher Disease Type I;   Cerebroside Lipidosis Syndrome;   Clucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme (imiglucerase for injection)
10 Recruiting International Collaborative Gaucher Group (ICGG) Gaucher Registry
Conditions: Gaucher Disease;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease
Intervention:
11 Recruiting Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Conditions: Gaucher Disease Type I;   Oxidative Stress
Intervention:
12 Completed Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease
Intervention: Drug: Imiglucerase
13 Completed Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: ISU302
14 Completed
Has Results
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV®
15 Completed A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease
Intervention:
16 Completed
Has Results
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
Condition: Gaucher Disease
Intervention: Drug: GA-GCB
17 Approved for marketing Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
18 Completed
Has Results
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
Condition: Gaucher Disease, Type 1
Intervention: Biological: GA-GCB (velaglucerase alfa)
19 Completed Safety Study of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
Condition: Gaucher Disease, Type 1
Intervention: Drug: AT2101
20 Recruiting This Study is to Evaluate the Effect of Velaglucerase Alfa (VPRIV®) on Patients With Type 1 Gaucher Disease Through the IV Administration of VPRIV® Over 2 Years
Condition: Gaucher Disease
Interventions: Drug: Velaglucerase alfa;   Dietary Supplement: 600 IU 25-hydroxyvitamin D

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years